65,437 trials
Chronic Obstructive Pulmonary Disease
Primary: Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD — 28 percentage of participants
Cerebrospinal Fluid Drainage Catheter
Primary: Composite Staff Evaluation Score (Anesthetist's Nontechnical Skills Global Rating Scale) — 10; 11; 2; 4 Participants
Idiopathic Pulmonary Fibrosis
Primary: The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12. — -0.00190; -0.00257 nanogram/ millitre/…
Depression
Primary: Beck Depression Inventory-II (BDI-II) — 29.9; 29.1; 11.0; 9.1 score on a scale
Depression
Primary: Change in Dim Light Melatonin Onset — 21.17; 20.77 decimal military time (hours) — p=0.2
Lennox-Gastaut Syndrome
Primary: Child Behavior Checklist (CBCL) Total Problem T-scores at the End of 2-year Treatment Period — 55.7; 54.8 score on a scale — p=0.6928
Sarcopenia
Primary: Change From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25 — 7.1; 7.3; 7.2; 7.3 Score on a scale — p=0.274
Cancer Survivor · Stage IA Breast Cancer · Stage IB Breast Cancer
Primary: Recruitment Rate — 18; 17 Participants
Anaemia
Primary: Part 1:Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Last Measurable Concentration (AUC[0-t]) and AUC From Zero Hours Extrapolated to Infinity AUC…
Endothelial Dysfunction · Aging · Bed Rest
Primary: Change of Delta Peak Blood Flow During sPLM — 91.9; -24.7 ml/min — p=0.0492
Cocaine Dependence
Primary: Number of Participants Who Report no Cocaine Use and Have no Cocaine Positive Urine Drug Screens in the Chantix Group Versus the Placebo Group Comparator During the Last…
Non-invasive Neuromodulation in Healthy Subjects
Primary: Percent Change of GABA Concentration in a Voxel Encompassing the Left Motor Cortex, Measured at 30 Min After rTMS — 8; -27 percent change
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Assay /Activity (rSBA) Against Neisseria Meningitidis Serogroup A, C, W-135 and Y (Using Baby Rabbit Complement) Titres ≥ the…
Malignant Hepatobiliary Neoplasm
Primary: Clinical Benefit Rate (Percentage), Which Includes Confirmed Tumor Response (Complete Response [CR] or Partial Response [PR]) or Stable Disease (SD) — 45.5 percentage of…
Hypoparathyroidism
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) — 13; 48 Participants